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Abstract
Artificial intelligence (AI)-based diagnostic algorithms have achieved ambitious aims
through automated image pattern recognition. For neurological disorders, this
includes neurodegeneration and inflammation. Scalable imaging technology for big
data in neurology is optical coherence tomography (OCT). We highlight that OCT
changes observed in the retina, as a window to the brain, are small, requiring rigor-
ous quality control pipelines. There are existing tools for this purpose. Firstly, there
are human-led validated consensus quality control criteria (OSCAR-IB) for OCT.
Secondly, these criteria are embedded into OCT reporting guidelines (APOSTEL).
The use of the described annotation of failed OCT scans advances machine learning.
This is illustrated through the present review of the advantages and disadvantages of
AI-based applications to OCT data. The neurological conditions reviewed here for
the use of big data include Alzheimer disease, stroke, multiple sclerosis (MS), Parkin-
son disease, and epilepsy. It is noted that while big data is relevant for AI, ownership
is complex. For this reason, we also reached out to involve representatives from
patient organizations and the public domain in addition to clinical and research cen-
ters. The evidence reviewed can be grouped in a five-point expansion of the OSCAR-
IB criteria to embrace AI (OSCAR-AI). The review concludes by specific recommen-
dations on how this can be achieved practically and in compliance with existing
guidelines.
Introduction
Sophisticated artificial intelligence (AI)-based algorithms
not only enable discrete layer segmentation of retinal
optical coherence tomography (OCT) scans, but can iden-
tify novel retinal features. A prominent recent example is
automatic clinic referral via deep learning based on retinal
layer analysis.1 The current OSCAR-IB quality control
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1
(QC) criteria take algorithmic quality components into
account (the A-criterion) but the criteria are not adapted
to AI-based algorithms.2 Given the recent success and
rapid developments in this field, it is timely to build on
the OSCAR-IB QC criteria to address the challenges of AI
and big data specifically.
To this purpose, it is critical to acknowledge that accu-
racy is paramount to the interpretation of retinal OCT in
neurological disease. Judgments are highly dependent on
quantitative data of individual retinal layers. Key compo-
nents are thickness, degree of change, and alteration of
the topography. The retinal layer thickness changes seen
in neurological disorders are much more subtle3-7 than
the pathologies seen in the ophthalmologic diseases, now
successfully detected by AI-based methods.1,8,9 For neu-
rodegenerative diseases, relevant annual retinal layer atro-
phy rates are just above the axial image resolution of
contemporary spectral-domain and swept-source OCT
techniques.5 For this reason, image QC is paramount.
Over the past decade, big OCT data have accumulated in
neurodegenerative and neuroinflammatory diseases. These
data are attractive for the development of AI strategies.
The expectation is to improve the accuracy of OCT-based
quantification, diagnostic sensitivity and specificity, dis-
cover novel surrogates for monitoring disease progression
as well as outcome metrics for clinical trials. Fully auto-
mated AI-based strategies are transferable from highly
specialized services to primary care. The test throughput
is also scalable to include, for example, high street opti-
cians. Both will aid with the logistics of patient care
through local centers.
In 2012, we proposed the first consensus OCT QC cri-
teria, OSCAR-IB.2 The name served as a mnemonic for
seven distinct QC criteria to be remembered; (i) Obvious
errors, (ii) Signal strength, (iii) Centration of scan, (iv)
Algorithm failure, (v) Retinal pathology, (vi) Illumina-
tion, and (vii) Beam placement. This was followed by
international validation10 and endorsement to reporting
guidelines.11 The OSCAR-IB QC criteria were developed
in a multiple sclerosis (MS) network, and have since been
broadly accepted. This success is at least in part due to
the demand for clarity and transparency on being practi-
cal to “get simple things right”. A similar approach is
warranted for the role of AI in relation to OCT data in
neurodegenerative diseases.
Review of evidence for need of QC
AI-based strategies are at risk for propagation of system-
atic errors, imbalance, and bias due to subtle differences
in data acquisition or postprocessing. There is justified
concern about the lack of QC standards for big data.12,13
The rise of big data is in part driven by the hope of
improving P4 medicine: predictive, preventive, personal-
ized, and participatory care.14 For example, integrative
prediction models encompassing as many as 63 variables
have been proposed to enable personalized predictions of
individuals’ outcomes and guide treatment decisions in
myeloproliferative neoplasms.15 The implications that AI-
driven approaches will have for individuals can easily be
influenced by bespoke sources of bias fed into the model
as discussed below.
Importantly, minimal variation in image acquisition
can cause substantial errors in the quantitative data.16,17
Strategies based on AI are excellent in recognizing
changes between images, but do not necessarily know
how the human OCT operators have acquired an image.
This can mislead the AI-based strategy with a downstream
effect of possible misdiagnosis, mismanagement, and
harm. The risk for such a situation to occur increases
with rapidly rising numbers of OCT scans to be evalu-
ated. It may introduce systematic errors if imbalances
exist between populations and centers, for example, due
to service capacity issues or automation of our health-care
systems. The possible medico-legal ramifications are also
evident.
Review of failures and successes of
retinal OCT in neurological diseases
To date, OCT data in MS and related disorders are most
consistent as most reports adhered to the OSCAR-IB QC
criteria and followed the APOSTEL reporting guide-
lines.2,11 Results are more heterogeneous for other neuro-
logical diseases because of lack of standardization. There
is evidence for an early publication bias in Alzheimer dis-
ease (AD) reports.6 Subsequent data were not supportive
of the earlier enthusiasm. Few of the reports on AD fol-
lowed a rigorous QC approach. This similarly applies to
reports of OCT in Parkinson disease (PD),18,19 amy-
otrophic lateral sclerosis (ALS),20-23 stroke,24 epilepsy,4,25
and schizophrenia.26
Review of successes of AI in
neurological diseases
There are critical successes for the use of AI in neurologi-
cal disease. For example, urgent triaging of individuals
from brain imaging to neurosurgery27; earlier diagnosis of
AD28; identifying suitable candidates for epilepsy sur-
gery29; and regulation of adaptive deep brain stimulation
in movement disorders.30 Imaging-based trial outcome
measures in neurology include almost all neurodegenera-
tive, neurovascular, and neuroinflammatory conditions
alongside tumors.31 Imaging data have become multi-
modal. This adds to complexity and time needed by
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human readers and reporting. Likewise, histological data
can now be used for machine and deep learning.32
The review committee
The ophthalmological community has driven advances in
AI-based analysis of retinal OCT.1 The committee for this
review has been expanded (Table 1). We included repre-
sentatives from neurological sub-specialties who have
used retinal OCT data for diagnostic and prognostic pur-
poses, as well as treatment trial outcome measures. We
have also engaged with experts in the fields of AI and
bio-engineering and bio-statistics and two not-for-profit
organizations (www.ern-eye.eu and www.imsvisual.org).
The patient voice
The importance of patient involvement as a key stake-
holder has been recognized33 and contributed to the
development of conceptual models.34 On a day-to-day
practical level, the experience has demonstrated that indi-
viduals tolerate retinal OCT well. It is noninvasive, non-
contact, quick, and provides instant feedback. The
possibility to display images directly to the individuals
and discuss changes has given them more confidence and
insight in their care.35 This good partnership has helped
in working together to build trust, supporting treatment
decisions and making OCT scans available for research.
There is a need to maintain this mutual trust at a time
where the immense amount of data accumulated now
permit AI-inspired projects on big data. None of this is
possible without patient participation, their consent, and
feedback. A key concern of patients and their advocates is
that their data will be misused. Individuals have a higher
level of confidence in not-for-profit stakeholders than in
government or private companies.36
Data protection and privacy
Due to the requirement of very large training datasets for
optimal performance, most current clinical AI systems
have been developed using routinely collected data which
have been anonymized. Anonymization of medical images
presents specific challenges, however, particularly images
of individually unique structures such as the neurosensory
retina.37 Even when carefully anonymized, there is at least
a theoretical risk of re-identification for such images,
either now or with some future technology.38 Therefore,
we recommend a multistep approach to addressing data
protection and privacy. Firstly, retinal OCT scans should
be anonymized according to current national and interna-
tional standards.39 This includes removal of any imaging
meta-data such as patient names, dates of birth, or
medical record numbers, obscuration of hospital visit
dates, plus careful consideration of any associated clinical
meta-data (e.g., merging of categories/classes if they con-
tain only a limited number of examples).40 Secondly, a
range of additional safeguards should be put in place.
Technical safeguards include the requirement to store
data in trusted research environments with access controls
and audit logs; contractual safeguards include prohibi-
tions against linkage or attempted re-identification of
data. Importantly, every attempt should be made to mini-
mize the data shared to that required for the clinical or
research purpose – this is a fundamental principle of
much data protection regulations, including the European
General Data Protection Regulation (GDPR). Finally –
and perhaps most importantly – it is vital to engage in
patient and public engagement and involvement at the
earliest possible stage. This includes making patients
aware that their data are being used for research, publish-
ing study protocols, and giving patients the opportunity
to opt-out. By adopting a cautious and engaged approach
such as this, we believe it is possible to reduce any data
protection risks while maximizing the potential for future
patient benefit. In the future, a range of technical solu-
tions, including federated learning and homomorphic
encryption, should help further mitigate these risks.41
Search strategy and selection criteria
We reviewed three databases, PubMed, Web of Science,
and Google Scholar, between 01 January 1963 and 23
April 2020 without language restriction. We chose the
English version of a manuscripts if the same group had
published similar data in Dutch, French, German, Italian,
or Spanish. The search terms used were “optical coher-
ence tomography” or “OCT” combined with “artificial
intelligence”, “machine learning”, “deep learning”, “multi-
ple sclerosis”, “optic neuritis”, “dementia”, “Alzheimer”,
“Parkinson”, “motor neuron disease”, “amyotrophic lat-
eral sclerosis”, “stroke”, “cerebrovascular accident”,
“schizophrenia”, “patient voice”. We also reviewed articles
included in three systematic reviews previously con-
ducted.3,5,8
Methods
Firstly, we reviewed the original OSCAR-IB criteria to
clarify which of the QC failures require an individual to
be re-assessed or to be excluded if, for example, post hoc
homogenization approaches fail. Having to recall a
patient for a failed test is not desirable, is problematic,
and is expensive. Secondly, we reviewed approaches to
rectifying QC failures by image postprocessing. Thirdly,
we examined the outcome of our AI-based methods for
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irregularities, identical to the approach taken in the origi-
nal OSCAR-IB report.2 The terminology of terms explic-
itly related to AI is summarized in Table 2.
Defining QC for AI: RASCO
Firstly, there is a clear and justified fear of the misuse of
big data.37 Secondly, the patient–physician relationship
must be supported to provide an optimal experience.
Thirdly, demonstration of the capability of the AI strategy
enhances the ability to produce high-quality and relevant
effectiveness research. Fourthly, it promotes accountabil-
ity. Fifthly, it provides grounding for the production of
reproducible studies. Together, the definition of QC for
AI can be summarized by five pillars which were named
individually or in combination in the literature reviewed
(Figure 1). The mnemonic, RASCO, stands for Repro-
ducibility (R), Accountability for decisions made (A), to
be Supportive of the patient–physician relationship (S),
Capability ranging from machine learning (ML)-sup-
ported OCT quality control assessment to time and
resource-efficient decision-making (C), and Openness
with and trust in public opinion (O) is pertinent, given
the personal data protection issues discussed above.42
Big data
The utility of AI in medical applications is more depen-
dent on data quality than quantity. The new research field
of big data has contributed considerably to the advance-
ment of medical science by analysis of large datasets.
Until recently, it had not been easy to accumulate enough
data to create a large data repository and analyses were
too complicated or lacked statistical and computer power.
A critical area of weakness of big data can be the granu-
larity and quality of the source data entered. In essence,
the quality of outputs or results of AI-based assessments
should not be expected to exceed the underlying quality
of the data being analyzed (input data). This underpins
the importance of maintaining the highest standards of
quality, even in the AI space. As we are at the dawn of AI
for OCT research, one of our aims is to facilitate the gen-
eration of the high-quality data needed for future research
in the field.
Prospective OCT image QC
Each OCT scan should prospectively be labeled as QC fail
or not. There are several reasons why a scan may fail QC.
Each failed scan should be annotated with a complete list
of reasons. An efficient way is to use the capital letters of
the OSCAR-IB criteria.10 To avoid a potential bias by
eliminating scans from the sickest individual who may
have difficulties with the test, this needs to be explicitly
noted. Retinal and systemic co-morbidities require careful
clinical evaluation with more in-depth ophthalmic pheno-
typing than hitherto done in most neurological studies.43
Table 1. Expertise of the literature review committees.
Expertise Members
Patient voice Nils Wiegerink (patient), Russel Wheeler (patient
advocate), Christiaan Waters (President of
patient organization), Avril Daily (Retina
International, ERN-EYE), Christina Fasser (Retina
International, ERN-EYE), Orla Galvin Deborah
(Retina International, ERN-EYE), and Oshakuade
(Retina International, ERN-EYE)





ALS Philip Albrecht and Orhan Atkas
Alzheimer disease Thomas Wisnewski
Epilepsy Josemir W. Sander
Parkinson disease Alexander Brandt, Philipp Albrecht, and Orhan
Atkas
Stroke Shadi Yaghi and Arvind CHANDRATHEVA
Multiple Sclerosis Alexander Brandt, Peter Calabresi, Laura Balcer,
Elliot & Tree Frohman, Friedeman Paul, Ari
Green, Pablo Villoslada, Axel Petzold, Philipp
Albrecht, Orhan Aktas, E. Ann Yeh, Bernardo
Sanchez-Dalmau, Jen Graves, Shiv Saidha,
Robert Bermel, IMSVISUAL, and ERN-EYE
Rare Diseases Alexander Brandt, Philipp Albrecht, Orhan Atkas,
Axel Petzold, Friedeman Paul, Frederike Oertel,
Alexander Brandt, E. Ann Yeh, Avril Daily
(Retina International, ERN-EYE), Christina Fasser
(Retina International, ERN-EYE), Orla Galvin
Deborah (Retina International, ERN-EYE)
Oshakuade (Retina International, ERN-EYE),
Bernardo Sanchez-Dalmau, and ERN-EYE
Ophthalmology Bernardo Sanchez-Dalmau, Pearse Keane,
Siegfried Wagner and ERN-EYE
Neuro-
ophthalmology
Fiona Costello, Ari Green, Axel Petzold, Laura
Balcer, Bernardo Sanchez-Dalmau, Jen Graves,
and ERN-EYE
OCT Alexander Brandt, Frederike Oertel, Hannah
Zimmerman, Philipp Albrecht, Orhan Atkas,
Peter Calabresi, Axel Petzold, Jen Graves,
Rachel Nolan-Kennedy, Laura Balcer, Shiv
Saidha, Bernardo Sanchez-Dalmau, Pablo
Villoslada, and Robert Bermel




Alexander Brandt, Friedeman Paul, Sven




David Crabb, Gary Cutter, Laura Balcer, Jen
Graves, Rachel Nolan-Kennedy, Kathryn
Fitzgerald, and Zhaoxia Yu
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QC failure may result in two situations: (1) where an
error can be corrected at postprocessing; and (2) where
the error requires recalling and repeating the test.
Human-led OCT image QC is a time-consuming task,
so it is desirable for this to be performed using AI
strategies. We suggest making use of the above-described
annotation of failed scans for ML of OSCAR-IB criteria
(Figure 2). This will enable the training of future AI
algorithms to separate good from insufficient quality
OCT scans. The next application step within the pool of
scans designated as being of inadequate quality will be to
identify those scans which may be subjected to post-ac-
quisition correction approaches, thereby making them
high quality, and enabling their safe and accurate utiliza-
tion. This is a crucial step as it allows for AI training in
auto-correction. Scans which failed OSCAR-IB and are
not correctable must be excluded from any further AI
steps.
Taken together this leaves a staged approach to QC in
AI: (1) Automated AI OCT QC rating using validated
OCT QC criteria2,10; (2) where possible AI QC correction
during image postprocessing, or if not possible patient
recall for repeat acquisition; and (3) final step of AI-based
image analysis. This will typically make use of pattern
recognition and be the key step forward for the primary
research questions. A limitation to keep in mind is that
Table 2. Terminology and basic concepts.
Artificial
Intelligence (AI)
Computer or machine-based intelligence which
enables “learning” and “problem solving”
Machine learning
(ML)
One subset of AI. Typically algorithms improve
automatically through experience after training
on a dataset. ML can be supervised or
unsupervised
Deep learning One subset of ML essentially based on artificial
neuronal networks. Very efficient and the basis
of most contemporary AI-based studies on
image recognition
Supervised Supervised ML works on a labeled training
dataset (e.g., OSCAR-IB OCT scans) and
reproduces the desired outcome
Unsupervised Unsupervised ML tries to discover previously
undetected patterns in a dataset
Over-fitting Over-fitting can be a problem with ML, a source
of over-enthusiastic reporting and reason for
lack of reproducibility
Figure 1. The goal of quality control in Artificial Intelligence (AI) rests on five pillars: RASCO. (1) Openness with and trust in the public opinion,
(2) to be Supportive for the patient–physician relationship, (3) Capability ranging from machine learning (ML)-supported OCT quality control
assessment to time and resource-efficient decision-making, (4) Accountability for decisions made, and (5) Reproducibility (RASCO).
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presently it is not possible to exclude ophthalmological
co-morbidities without a clinical assessment.
AI artifact vulnerability
We have not identified reports on the vulnerability of
algorithms to misclassification due to the use of different
OCT devices or software versions. Even seemingly small
updates have the potential to cause significant differences
which if left unnoticed can bias results.44
Ground truth
The definition of ground truth is disease-specific. It
should be stated explicitly how the ground truth was
defined. At the minimum for AD and other neurodegen-
erative dementias, epilepsy, MS, optic neuritis (ON), neu-
romyelitis optica spectrum disorder (NMOSD), PD,
adherence to consensus investigation protocols, and diag-
nostic criteria will be required. As diagnostic criteria in
most neurological diseases are regularly updated, this
needs to be taken into account.
Statistics
The descriptive statistics reviewed were mostly based on
binary classifiers such as a disease is present “yes/no”.
These models should include a comment on proportional
bias.45 This is needed to interrogate how much the AI-
based prediction agrees with the ground truth. The defini-
tion for an acceptable ground truth needs to include the
level of evidence on which it was based. For binary and
multiclassifier models, the degree of inter-rater agreement
should be stated to permit judging on how stable the
ground is.
Graphs can be presented in a way that allows judgment
of the degree of over-fitting and underestimation relevant
in comparing differences between AI and ground truth.
Many studies used Bland-Altman plots46 or analyzed the
performance of AI and ground truth based on a receiver
operator curve (ROC)-based area under the curve (AUC).
This gives comparative estimates of sensitivity, specificity,
and the positive predictive value (PPV) as a measure of
overall accuracy. This is particularly relevant for relatively
rare diseases. It was recommended to complementing area
Figure 2. The capability of AI to contribute interpreting OCT images depends on the optimization of each step contributing to the decision tree.
The first step relates to the quality of the raw data. Validated QC criteria for OCT image have been summarized as OSCAR-IB.2 The ground truth
of whether or not an OCT passes QC is based on human assessment. The seven OSCAR-IB criteria for QC rejection by a human assessor can
directly be used to train AI. Annotation of corrupted OCT scans permits for two outcomes: (1) image postprocessing and repair of artifacts or (2)
complete rejection and (if feasible) recall of patient and OCT rescan. Only a dataset that passed OCT image QC should be used for further AI
interpretation.
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under the curve ROC (AUROC) values by precision-recall
(precision is the PPV and recall is the sensitivity in the AI
literature) curves (AUPRC).8 This was found to be of rel-
evance for unbalanced datasets (substantially more sub-
jects in one of the groups compared).
Cut-off level calculation
Reporting of calculation of cut-off values included the use
of independent cohorts, a graphical ROC-based approach,
the Youden Index, k-fold cross-validation, or hold-out
validation approaches to obtain accurate estimations of
AI-based cut-off performance.
Power calculations
We did not yet find consistent reports of the inclusion of
power calculations to studies, which are relevant for ran-
domized controlled trials using AI-based outcome mea-
sures.47 It is recommended that sample size estimates be
performed before developing an algorithm and repeated
after study completion. The gain in power, meaning a
more robust statistical result, is just as informative for
future research as the potential cost savings by optimizing
numbers. Lastly, the standardized effect size, likely to
come from AI, was recommended to be aligned with dis-
tribution, and anchor health economics to inform clinical
trials on what will be a realistic difference.47,48
Cohort description
On review, cohort descriptions were mostly conform to
contemporary standards on demographic characteristics.
Cohort descriptions are relevant for AI, and will also
greatly limit/determine the usability of the system. This
reinforces the need to build on successful initiatives such
as the established Consolidated Standards of Reporting
Trials of Electronic and Mobile Health Applications and
online TeleHealth (CONSORT-EHEALTH)49 and the
CONSORT-AI guidelines.50 Documentation of develop-
mental changes is also relevant throughout pediatric care
and at the transition to adult care. A novel source of
potential biases related to the disease diagnostic criteria
used. For many of the conditions of interest to retinal
OCT, subsequent diagnostic criteria were published over
the past decades. While generally aimed at improving
practicability, sensitivity, and specificity, this bears the
risk that cohorts which are supposed to have the same
disease can be quite different in their composition. For
example, subsequent diagnostic criteria for MS, AD, and
PD have profoundly reshaped the patient base for clinical
research over time. Contemporary cohorts tend to be
milder than historical cohorts.51 Clinical trial populations
are different from observational studies. The co-morbidity
burden is relevant. Relevant items for the pooling of big
data are: reporting of the exact diagnostic criteria, a
detailed listing of all inclusion and exclusion criteria,
recruitment, referrals, and capability of individuals to
comply with the examinations. Minimization of the risk
of systematic bias will ensure that validation of AI in
other cohorts will be comparable.
Validation
For all AI algorithm development efforts, data used for
this purpose should be clearly described for discovery and
replication analyses. To avoid obtaining a distorted/biased
view on performance, data that are used for validation
(e.g., to assess performance) should not have been used
during algorithm development. There is a real risk for
over-fitting the AI models. It was recommended to per-
form a validation of the algorithm with the aid of a com-
parable out-of-sample population. Each AI classification
scheme should be rated to whether or not an external
validation was performed. This can be supported by pub-
lishing details on the building blocks of the AI. Relevant
are precise and meaningful definitions on a functional
and performance level. This entails a detailed description
of the AI architecture, hyper-parameters, as well as details
on how the available data were used to train such sys-
tems, preferably via open access code repositories. One of
the challenges with AI at regulatory level but also at the
clinical level found was the fact that neural networks can
learn with data and improve their performance. For this
reason, it was suggested to define in advance which type
of learning is allowed without requiring validation,
approval, or lack clinical risks.
Human versus machine and human
with machine
It was reported that AI might improve over human per-
formance in terms of accuracy and speed.52 For this “ma-
chine versus human” approach reporting included data
on sensitivity, specificity, positive, and negative predictive
values including the 95% confidence intervals (CI) and
the numbers on which the calculations were based. These
data permit to answer the question if AI can outperform
humans not only as seen with Chess and “Go” games,53,54
but also for classification of retinal appearances.55
There is a second, equally important question to be
answered. How can AI be used to enhance human perfor-
mance?56 Therefore, it was recommended to test if there
is a synergistic effect if the AI and human approach are
combined. This is typically referred to as human–AI sym-
biont/symbiotic.57
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Clinical practice
The relevance of potential clinical downstream effects has
been recognized.58-60 The big chances are to reduce the
burdens on physicians and help with service capacity
issues. It was recommended to indicate if an algorithm is
useful for clinical practice. This requires to test the algo-
rithm in clinical routine. There were different levels at
which algorithms added information: on an individual
level, on a cohort level, or for screening purposes. There
can be important consequences for daily clinical care and
health systems. Concerns reported related to misdiagnosis
and practicability. This has implications for disease classi-
fication.61
Guidelines
At the time of the review, the following guidelines were
relevant: APOSTEL, TRIPOD-AI, CONSORT-AI,50
SPIRIT-AI, and STROBE62 guidelines. They are regularly
updated and latest information can be found on the
equator network website at www.equator-network.org/.
Open access
Open access and data sharing were found to be essential for
accountability and reproducibility. The classified sample
dataset is just as valuable as the developed algorithm. Data-
sets can potentially be used by other groups, to facilitate
even greater improvements. Accordingly, data availability
may accelerate development in the field. Algorithms can
also be transferable and codes can be shared.
Black box
On review, there is a need to understand on what basis
an algorithm came to a particular conclusion.
Review of the black box of OCT in
neurology
There are a few careful predictions one can make regard-
ing the “black box” for neurodegeneration based on anat-
omy and progression pattern.
Firstly, anatomically each area in the retina is con-
nected by axons with a corresponding area in the brain
because of the hard-wired retino-cortical projections.3,5
The location of damage to the brain will determine the
location of expected OCT changes in a determined area
of the retina, a “Region of Interest” (ROI). It has been
shown that an ROI-based approach to quantification of
inner retinal layer atrophy is superior to occasionally per-
formed sector analysis5-7 or the generally adopted global
averaged approach because it can mask small areas of
atrophy.63,64
Secondly, the progression pattern is determined by
location and size of a lesion damaging the retino-cortical
projections.64-66 The speed of progression is highest and
the area of inner retinal atrophy most extensive with
direct retrograde axonal degeneration as seen with optic
nerve damage. More distal brain damage will still cause
localized atrophy in the retina by a mechanism called ret-
rograde trans-synaptic axonal degeneration.65,67 On
sequential OCT imaging, the time course of atrophy is
shorter with small brain lesions compared to larger brain
lesions.64 It can be anticipated that a smoldering, slowly
enlarging brain lesion will continue to drive the expan-
sion of OCT detectable retinal atrophy.68
Thirdly, inflammatory activity in demyelinating disease
has been related to transient increase of the inner nuclear
layer (INL) volume.69-73 Part of this INL thickening is
related to the development of microcystic macular edema
(MME).69,70,74 Vitreous traction had been implicated, but
is not required for the development of MMO.75 In most
(>80%) cases, MMO is a transient phenomenon.74 In the
remainder, it remains static over the years74,76 and is con-
sidered by some to represent a retrograde maculopathy77
due to axonotmesis in the anterior visual pathways as
known from experimental models.78
Fourthly, there are qualitative observations on the OCT
images, which have not yet been translated into auto-
mated forms of quantification. One example is the pres-
ence of hyper-reflective spots.74 There are two types of
these hyper-reflective spots on OCT, and one is static and
particularly visible at the upper and lower border of the
INL. With the advent of OCT-Angiography (OCTA) and
adaptive optics, it has become clear that they represent
reflectivity changes from the inner retinal vasculature.79
There is at least another type of hyper-reflective spot
noticed on serial OCT images, which migrates vertically
through the retina.
Fifthly, the vitreous has specific OCT signal characteris-
tics which can be reliably quantified from the raw image
data.80,81 The technique is useful in neurological disease
affecting younger adults where the vitreous body still
adheres to the retina such as the majority of people with
MS.82 The evaluation of the raw OCT data, rather than
analysis of an already postprocessed screen image, is
required due to signal changes.
Sixth, advanced image shape analyses now permit for
quantitative data on qualitative characteristics of the optic
disc. The technique has proved valuable in idiopathic
intracranial hypertension83,84 and possibly also idiopathic
moyamoya angiopathy.85 Similarly, the presence of peri-
papillary hyper-reflective ovoid mass-like structures
(PHOMS) is a novel OCT finding,86 which akin to MMO
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remained undetectable on conventional funduscopic
examination. Likewise, shape analysis of the fovea has
become possible.87,88
Seventh, functional assessment of individual retinal lay-
ers by OCT is possible using, for example, a dark adapta-
tion.79 One can anticipate that with the availability of
OCTA, the retinal equivalent of a blood-oxygen-level-de-
pendent (BOLD) signal for the brain will emerge.89
Increased, localized retinal metabolic activity will demand
increased oxygen supply and cause elevated perfusion of
the microvasculature.79 Pioneering data on OCTA in MS
imply that there is a need for AI-supported QC to
exclude artifacts.90-92 This will be relevant for reliable
quantitative OCTA data on the retinal microvasculature
which may help to differentiate between disease entities
such as MS and NMOSD.93
Eighth, inter-eye differences of individual retinal layers
are an attractive and highly sensitive method to screen for
optic neuritis and MS.43,94-101 Expanding on these find-
ings, there is a field for AI-based analyses of patterns of
retinal asymmetry in MS.43
Lastly, reflectivity changes of individual layers can be
interrogated to estimate tissue properties indirectly.102,103
Based on the above combination of numerous quanti-
tative and qualitative changes in retinal (neural and non-
neural tissue) architecture in neurological disease, there
are promising avenues for a supervised ML approach to
the analysis and interpretation of OCT data. Equally, for
researchers who prefer to follow a nonsupervised ML
approach, the committee recommends checking if find-
ings may be explainable, at least in part, by the above
summary of anatomically, biologically, and pathologically
plausible observations.
Summary
In summary, we reviewed several levels of AI-based OCT
research in neurology. The main points arising from this
review are summarized in Table 3 and based on five pil-
lars (RASCO). The practical conclusions from the multi-
ple levels of evidence reviewed and the summary table
may be found helpful on a practical level for future
research in the field.
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Table 3. Summary of key points from the literature review on OCT
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Question Answer
REPRODUCIBLITY
OSCAR-IB OCT quality control compliant? Yes / No
APOSTEL OCT reporting guideline compliant? Yes / No
TRIPOD-AI compliant? Yes / No
CONSORT-AI compliant? Yes / No
SPIRIT-AI compliant? Yes / No
STROBE compliant? Yes / No
ACCOUNTABILITY
Training, test & validation sets explained? Yes / No
Potential for bias1 in big data addressed? Yes / No
Ground truth explicitly stated? Yes / No
Statement on proportional bias given? Yes / No
Precision-recall curves provided? Yes / No
Power calculations included? Yes / No
SUPPORTS PATIENT DOCTOR RELATIONSHIP
Patient voice included? Yes / No
Conflicts of interest, including political, explained? Yes / No
Shows how AI is used to enhance human performance? Yes / No
Tested in clinical practice? Yes / No
CAPABILITY OF ALGORITHM
Unsupervised AI?2 Yes / No
Has QC capabilities?3 Yes / No
Provides a glimpse into the black box?4 Yes / No
Vulnerabilities of AI explained?5 Yes / No
External Validation? Yes / No
OPENNESS
Data availability statement? Yes / No
Data deposited in repository? Yes / No
AI deposited in open access code repository? Yes / No
1Sources of bias can be analytical, clinical, statistical, imbalance in




5Vulnerabilities to artifacts, use of different devices, hard- or software
updates of the OCT device.
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 9
A. Petzold et al. OSCAR-AI
Isabelle Audo, Jagannadha Avasarala, Daly Avril, Fran-
cesca R. Bagnato, Brenda Banwell, Amit Bar-Or, Raed
Behbehani, Arnaldo Belzunce Manterola, Jeffrey Bennett,
Leslie Benson, Jacqueline Bernard, Dominique Bremond-
Gignac, Josefine Britze, Jodie Burton, Jonathan Calkwood,
William Carroll, Arvind Chandratheva, Jeffrey Cohen,
Giancarlo Comi, Christian Cordano, Silvana Costa, Fiona
Costello, Ardith Courtney, Anes Cruz-Herranz, Gary Cut-
ter, David Crabb, Lindsey Delott, Jerome De Seze, Ricarda
Diem, Helene Dollfuss, Nabil K. El Ayoubi, Christina Fas-
ser, Carsten Finke, Dominik Fischer, Kathryn Fitzgerald,
Pedro Fonseca, Jette L. Frederiksen, Elliot Frohman, Ter-
esa Frohman, Kazuo Fujihara, I~nigo Gabilondo Cuellar,
Steven Galetta, Elena Garcia-Martin, Gavin Giovannoni,
Brigita Glebauskiene, Ines Gonzalez Suarez, Gorm Pihl
Jensen, Steffen Hamann, Hans-Peter Hartung, Joachim
Havla, Bernhard Hemmer, Su-Chun Huang, Jaime Imi-
tola, Vytautas Jasinskas, Hong Jiang, Rahele Kafieh, Lud-
wig Kappos, Randy Kardon, David Keegan, Eric
Kildebeck, Ungsoo Samuel Kim, Sasha Klistorner, Ben-
jamin Knier, Scott Kolbe, Thomas Korn, Lauren Krupp,
Wolf Lagreze, Letizia Leocani, Netta Levin, Petra Liskova,
Jana Lizrova Preiningerova, Birgit Lorenz, Eugene May,
David Miller, Janine Mikolajczak, Saddek Mohand Sa€ıd,
Xavier Montalban, Mark Morrow, Ellen Mowry, Joaquim
Murta, Carlos Navas, Rachel Nolan, Katarzyna Nowo-
miejska, Frederike Cosima Oertel, Jiwon Oh, Celia Oreja-
Guevara, Christophe Orssaud, Benjamin Osborne, Olivier
Outteryck, Catarina Paiva, Jacky Palace, Athina Papado-
poulou, Nikos Patsopoulos, Jana Lizrova Preiningerova,
Nikolas Pontikos, Markus Preising, Jerry Prince, Daniel
Reich, Robert Rejdak, Marius Ringelstein, Luis Rodriguez
de Antonio, Jose-Alain Sahel, Bernardo Sanchez-Dalmau,
Jaume Sastre-Garriga, Sven Schippling, Joel Schuman,
Ken Shindler, Robert Shin, Neil Shuey, Kerstin Soelberg,
Svenja Specovius, Agnese Suppiej, Alan Thompson,
Ahmed Toosy, Ruben Torres, Valerie Touitou, Susanne
Trauzettel-Klosinski, Anneke van der Walt, Patrick Verm-
ersch, Angela Vidal-Jordana, Amy T. Waldman, Christian
Waters, Russell Wheeler, Owen White, Helmut Wilhelm,
Kimberly M. Winges, Nils Wiegerinck, Lenja Wiehe, Tho-
mas Wisnewski, Sui Wong, Jens W€urfel, Shadi Yaghi,
Yuyi You, Zhaoxia Yu, Patrick Yu-Wai-Man, Reda
Zemaitien_e, and Hanna Zimmermann. More details about
these collaborators are provided in Text S1.
Author Contributions
Axel Petzold: Study concept and design, project supervi-
sion, monthly project meetings, review of literature, draft-
ing of manuscript, and revisions of manuscript. Phillip
Albrecht: Monthly project meetings, review of literature,
intellectual content, and revisions of manuscript. Laura
Balcer: Monthly project meetings, review of literature,
intellectual content, and revisions of manuscript. Erik
Bekkers: Review of literature, intellectual content, and
revisions of manuscript. Alexander U. Brandt: Monthly
project meetings, review of literature, intellectual content,
and revisions of manuscript. Peter A. Calabresi: Monthly
project meetings, review of literature, intellectual content,
and revisions of manuscript. Orla Galvin Deborah:
Patient perspective, revision of content, and final version
of the manuscript. Jennifer S. Graves: Monthly project
meetings, review of literature, intellectual content, and
revisions of manuscript. Ari Green: Critical revision of
the manuscript for important intellectual content. Pearse
A. Keane: Critical revision of the manuscript for impor-
tant intellectual content. Jenny A. Nij Bijvank: Critical
revision of the manuscript for important intellectual con-
tent. Friedemann Paul: Monthly project meetings, review
of literature, intellectual content, and revisions of manu-
script. Shiv Saidha: Monthly project meetings, review of
literature, intellectual content, and revisions of manu-
script. Josemir W. Sander: Critical revision of the manu-
script for important intellectual content. Pablo Villoslada:
Monthly project meetings, review of literature, intellectual
content, and revisions of manuscript. Siegfried K. Wag-
ner: Critical revision of the manuscript for important
intellectual content. E. Ann Yeh: Monthly project meet-
ings, review of literature, intellectual content, and revi-
sions of manuscript.
Conflict of Interest
A. Petzold is part of the steering committee of the ANGI
network which is sponsored by ZEISS, steering committee
of the OCTiMS study which is sponsored by Novartis, and
reports speaker fees from Heidelberg Engineering. P.
Albrecht reports consulting fees, research grants, and non-
financial support from Allergan, Biogen, Celgene, Ipsen,
Merck Serono, Merz Pharmaceuticals, Novartis, and
Roche, consulting fees, and nonfinancial support from
Bayer Healthcare, and Sanofi-Aventis/Genzyme, outside
the submitted work. L. Balcer reports personal fees from
Biogen; she is editor in chief of the Journal of Neuro-Oph-
thalmology. E. Bekkers has nothing to disclose. A. Brandt
is cofounder and shareholder of startups Motognosis and
Nocturne. He is named as inventor on several patent
applications description MS serum biomarkers, perceptive
visual computing, and retinal image analysis. R. Bremel
has served as a consultant for Biogen, EMD Serono, Gen-
zyme/Sanofi, Genentech/Roche, Novartis, and Viela Bio.
He receives ongoing research support directed to his insti-
tution from Biogen, Genentech, and Novartis. P.A. Cal-
abresi has received consulting fees for serving on scientific
advisory boards for Biogen and Disarm Therapeutics, and
10 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
OSCAR-AI A. Petzold et al.
is PI on grants to Johns Hopkins from Biogen, Gentech,
and Annexon. O. Galvin has nothing to disclose. J.S.
Graves has grant/contract research support from the
National MS Society, Biogen, and Octave Biosciences. She
serves on a steering committee for a trial supported by
Novartis. She has received honoraria for a nonpromo-
tional, educational activity for Sanofi-Genzyme. She has
received speaker fees from Alexion and BMS and served
on an advisory board for Genentech. A. Green reports
grants and other support from Inception Biosciences;
grants from the National Multiple Sclerosis Society and
from the US. National Institutes of Health; additional sup-
port from MedImmune, Mylan, Sandoz, Dr Reddy,
Amneal, Momenta, Synthon, and JAMA Neurology, out-
side the submitted work; and that the Multiple Sclerosis
Center, Department of Neurology, University of California
San Francisco has received grant support from Novartis
for participating in the OCTIMS study. P.A. Keane is sup-
ported by a Clinician Scientist award (CS-2014-14-023)
from the National Institute for Health Research. J. Nij Bij-
vank has nothing to disclose. J.W. Sander has been con-
sulted by and received research grants and fees for lectures
from Eisai, UCB, Zogenix, and GW Pharmaceuticals, out-
side the submitted work. F. Paul receives funding from
Deutsche Forschungsgemeinschaft, Bundesministerium f€ur
Bildung und Forschung, and Guthy Jackson Charitable
Foundation. FC has received consulting fees from Clene,
EMD Serono, and PRIME, and is participating as a site
investigator in the Novartis-funded OCTIMS study. S.
Saidha has received consulting fees from Medical Logix for
the development of CME programs in neurology and has
served on scientific advisory boards for Biogen-Idec, Gen-
zyme, Genentech Corporation, EMD Serono, and Celgene.
He was the site investigator of a trial sponsored by Med-
Day Pharmaceuticals, and is the PI of investigator-initiated
studies funded by Genentech Corporation and Biogen
Idec, and received support from the Race to Erase MS
foundation. He has received equity compensation for con-
sulting from JuneBrain LLC, a retinal imaging device
developer. P. Villoslada has received an honorarium from
Heidelberg Engineering in 2014, has received unrestricted
research grants from Novartis (including for the OCTIMS
study), Biogen, Genzyme, and Roche, and has participated
in advisory boards for Novartis, Roche, Genzyme, and
Biogen. PVi holds stocks in the following spin-off compa-
nies: Bionure Inc, Spire Bioventures, Mintlabs, and Health
Engineering. S. Wagner has nothing to disclose. E. Ann
Yeh has received research funds from NMSS, CIHI, CIHR,
NIH, OIRM, MS Society of Canada, Mario Battaglia Foun-
dation, SickKids Foundation, CBMH Innovation Fund,
CMSC, Stem Cell Network, Department of Defense, Rare
Diseases Foundation, and Biogen. Unrestricted educational
funds from Teva and Guthy-Jackson Foundation. She has
served on a scientific advisory panel for Hoffmann-La
Roche and Biogen and has received speaker’s honoraria





1. Fauw JD, Ledsam JR, Romera-Paredes B, et al. Clinically
applicable deep learning for diagnosis and referral in
retinal disease. Nat Med 2018;24:1342–1350.
2. Tewarie P, Balk L, Costello F, et al. The OSCAR-IB
consensus criteria for retinal OCT quality assessment.
PLoS One 2012;7:e34823.
3. Petzold A, de Boer JF, Schippling S, et al. Optical
coherence tomography in multiple sclerosis: a systematic
review and meta-analysis. Lancet Neurol 2010;9:921–932.
4. Peng Y, Zhao Y, Hu W, et al. Reduction of retinal nerve
fiber layer thickness in vigabatrin-exposed patients: a
meta-analysis. Clin Neurol Neurosurg 2017;157:70–75.
5. Petzold A, Balcer LJ, Calabresi PA, et al. Retinal layer
segmentation in multiple sclerosis: a systematic review
and meta-analysis. Lancet Neurol 2017;16:797–812.
6. Chan VT, Sun Z, Tang S, et al. Spectral-domain OCT
measurements in Alzheimer’s disease. Ophthalmology
2019;126:497–510.
7. Chrysou A, Jansonius NM, van Laar T. Retinal layers in
Parkinson’s disease: a meta-analysis of spectral-domain
optical coherence tomography studies. Parkinsonism Relat
Disord 2019;64:40–49.
8. Liu X, Faes L, Kale AU, et al. A comparison of deep
learning performance against health-care professionals in
detecting diseases from medical imaging: a systematic
review and meta-analysis. The Lancet Digital Health
2019;1:e271–e297.
9. Milea D, Najjar RP, Jiang Z, et al. Artificial intelligence to
detect papilledema from ocular fundus photographs. N
Engl J Med 2020;382(18):1687–1695.
10. Schippling S, Balk L, Costello F, et al. Quality control for
retinal OCT in multiple sclerosis: validation of the
OSCAR-IB criteria. Mult Scler 2015;21:163–170.
11. Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, et al. The
APOSTEL recommendations for reporting quantitative
optical coherence tomography studies. Neurology
2016;86:2303–2309.
12. Editors TL. Expression of concern: Hydroxychloroquine
or chloroquine with or without a macrolide for treatment
of COVID-19: a multinational registry analysis. Lancet
(London, England): 2020.
13. Mehra MR, Desai SS, Kuy SR, et al. Cardiovascular
disease, drug therapy, and mortality in Covid-19. N Engl
J Med 2020;382(25):e102.
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 11
A. Petzold et al. OSCAR-AI
14. Hood L, Flores M. A personal view on systems medicine
and the emergence of proactive P4 medicine: predictive,
preventive, personalized and participatory. New
Biotechnol 2012;29:613–624.
15. Grinfeld J, Nangalia J, Baxter EJ, et al. Classification and
personalized prognosis in myeloproliferative neoplasms.
N Engl J Med 2018;379:1416–1430.
16. Balk LJ, de Vries-Knoppert WAEJ, Petzold A. A simple
sign for recognizing Off-Axis OCT measurement beam
placement in the context of multicentre studies. PLoS
One 2012;7:e48222.
17. Oberwahrenbrock T, Weinhold M, Mikolajczak J, et al.
Reliability of intra-retinal layer thickness estimates. PLoS
One 2015;10:e0137316.
18. Albrecht P, M€uller A-K, S€udmeyer M, et al. Optical
coherence tomography in Parkinsonian syndromes. PLoS
One 2012;7:e34891.
19. Borm CD, Smilowska K, de Vries NM, et al. The neuro-
ophthalmological assessment in Parkinson’s disease. J
Parkinson’s Dis 2019;9:427–435.
20. Roth NM, Saidha S, Zimmermann H, et al. Optical
coherence tomography does not support optic nerve
involvement in amyotrophic lateral sclerosis. Eur J
Neurol 2013;20:1170–1176.
21. Ringelstein M, Albrecht P, S€udmeyer M, et al. Subtle
retinal pathology in amyotrophic lateral sclerosis. Ann
Clin Transl Neurol 2014;1(4):290–297.
22. H€ubers A, M€uller HP, Dreyhaupt J, et al. Retinal
involvement in amyotrophic lateral sclerosis: a study with
optical coherence tomography and diffusion tensor
imaging. J Neural Transm 1996;2016(123):281–287.
23. Simonett JM, Huang R, Siddique N, et al. Macular sub-
layer thinning and association with pulmonary function
tests in Amyotrophic Lateral Sclerosis. Sci Rep
2016;6:29187.
24. Pula JH, Yuen CA. Eyes and stroke: the visual aspects of
cerebrovascular disease. Stroke Vasc Neurol 2017;2:210–
220.
25. Clayton LM, Devile M, Punte T, et al. Retinal nerve fiber
layer thickness in vigabatrin-exposed patients. Ann
Neurol 2011;69:845–854.
26. Silverstein SM, Rosen R. Schizophrenia and the eye.
Schizophrenia Res Cognition 2015;2:46–55.
27. Chilamkurthy S, Ghosh R, Tanamala S, et al. Deep
learning algorithms for detection of critical findings in
head CT scans: a retrospective study. The Lancet
2018;392(10162):2388–2396.
28. Marinescu RV, Oxtoby NP, Young AL, et al. TADPOLE
Challenge: Accurate Alzheimer’s disease prediction
through crowdsourced forecasting of future data,
Predictive intelligence in medicine : second International
Workshop. PRIME 2019, held in Conjunction with
MICCAI 2019, Shenzhen, China, October 13, 2019,
Proceedings. PRIME (Workshop) (2nd : 2019 : Shenzhen
Shi, China) 2019;11843:1–10.
29. Rasheed K, Qayyum A, Qadir J, et al. Machine learning
for predicting epileptic seizures using EEG signals: a
review. IEEE Rev Biomed Eng 2021;14:139–155.
30. Neumann W-J, Turner RS, Blankertz B, et al. Toward
electrophysiology-based intelligent adaptive deep brain
stimulation for movement disorders. Neurotherapeutics
2019;16:105–118.
31. Bashyam VM, Erus G, Doshi J, et al. MRI signatures of
brain age and disease over the lifespan based on a deep
brain network and 14 468 individuals worldwide. Brain.
2020;143:2312–2324.
32. Cornblath EJ, Robinson JL, Irwin DJ, et al. Defining and
predicting transdiagnostic categories of neurodegenerative
disease. Nat Biomed Eng 2020;4:787–800.
33. Dean S, Mathers JM, Calvert M, et al. "The patient is
speaking": discovering the patient voice in
ophthalmology. Br J Ophthalmol 2017;101:700–708.
34. Deverka PA, Lavallee DC, Desai PJ, et al. Stakeholder
participation in comparative effectiveness research:
defining a framework for effective engagement. J Comp
Eff Res 2012;1:181–194.
35. Braithwaite T, Wiegerinck N, Petzold A, Denniston A.
vision loss from atypical optic neuritis: patient and
physician perspectives. Ophthalmology and Therapy
2020;9(2):215–220.
36. Courbier S, Dimond R, Bros-Facer V. Share and protect
our health data: an evidence based approach to rare
disease patients’ perspectives on data sharing and data
protection-quantitative survey and recommendations.
Orphanet J Rare Dis 2019;14:175.
37. Tom E, Keane PA, Blazes M, et al. Protecting data
privacy in the age of AI-enabled ophthalmology. Transl
Vis Sci Technol 2020;9:36.
38. Larson DB, Magnus DC, Lungren MP, et al. Ethics of
using and sharing clinical imaging data for artificial
intelligence: a proposed framework. Radiology
2020;295:675–682.
39. Information Commissioner’s Office. Anonymisation:
managing data protection risk code of practice. https://ic
o.org.uk/media/1061/anonymisation-code.pdf. Accessed
December 31, 2020.
40. Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG.
Preparing raw clinical data for publication: guidance for
journal editors, authors, and peer reviewers. Trials
2010;11.
41. Kaissis GA, Makowski MR, R€uckert D, Braren RF.
Secure, privacy-preserving and federated machine
learning in medical imaging. Nature Machine Intelligence
2020;2:305–311.
42. Lewis P, Conn D, Pegg D. (2020). UK government using
confidential patient data in coronavirus "Response.
12 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
OSCAR-AI A. Petzold et al.
43. Petzold A, Chua SYL, Khawaja AP, et al. Retinal
asymmetry in multiple sclerosis. Brain 2020.
44. Coric D, Petzold A, Uitdehaag BMJ, Balk LJ. Software
updates of OCT segmentation algorithms influence
longitudinal assessment of retinal atrophy. J Neurol Sci
2018;387:16–20.
45. Yu M, Tham Y-C, Rim TH, et al. Reporting on deep
learning algorithms in health care. The Lancet Digital
Health 2019;1:e328–e329.
46. Bland JM, Altman DG. Applying the right statistics:
analyses of measurement studies. Ultrasound Obstet
Gynecol 2003;22:85–93.
47. Cook JA, Julious SA, Sones W, et al. DELTA,
javax.xml.bind.JAXBElement@5af99c39, guidance on
choosing the target difference and undertaking and
reporting the sample size calculation for a randomised
controlled trial. BMJ (Clinical research ed.) 2018;363:k3750.
48. Cook JA, Hislop J, Adewuyi TE, et al. Assessing methods
to specify the target difference for a randomised
controlled trial: DELTA (Difference ELicitation in TriAls)
review. Health Technol Assess 2014;18(28):1–175.
49. Eysenbach G. CONSORT-EHEALTH: Improving and
Standardizing Evaluation Reports of Web-based and Mobile
Health Interventions. J Med Internet Res 2011;13:e126.
50. CONSORT-AI and Group, S.-A. S. Reporting guidelines
for clinical trials evaluating artificial intelligence
interventions are needed. Nat Med 2019;25:1467–
1468.
51. Beiki O, Frumento P, Bottai M, et al. Changes in the risk
of reaching multiple sclerosis disability milestones in
recent decades: a nationwide population-based cohort
study in Sweden. JAMA Neurol 2019;76:665–671.
52. Cook TS. Human versus machine in medicine: can
scientific literature answer the question? The Lancet
Digital Health 2019;1:e246–e247.
53. Silver D, Huang A, Maddison CJ, et al. Mastering the
game of Go with deep neural networks and tree search.
Nature 2016;529:484–489.
54. Gibney E. What Google’s winning Go algorithm will do
next. Nature 2016;531:284–285.
55. Biousse V, Newman NJ, Najjar RP, et al. Optic disc
classification by deep learning versus expert neuro-
ophthalmologists. Ann Neurol 2020.
56. Asan O, Bayrak AE, Choudhury A. Artificial intelligence
and human trust in healthcare: focus on clinicians. J Med
Internet Res 2020;22:e15154.
57. Nagao K. Symbiosis between Humans and Artificial
Intelligence. In ed. Artificial Intelligence Accelerates
Human Learning. Springer, 2019.
58. Singh H, Meyer AND, Thomas EJ. The frequency of
diagnostic errors in outpatient care: estimations from
three large observational studies involving US adult
populations. BMJ Quality Safety 2014;23:727–731.
59. Liang H, Tsui BY, Ni H, et al. Evaluation and accurate
diagnoses of pediatric diseases using artificial intelligence.
Nat Med 2019;25:433–438.
60. Gruber K. Is the future of medical diagnosis in computer
algorithms? The Lancet Digital Health 2019;1:e15–e16.
61. Sanchez-Martinez S, Camara O, Piella G, et al. Machine
Learning for Clinical Decision-Making: Challenges and
Opportunities, 2019.
62. Little J, Higgins JPT, Ioannidis JPA, et al. STrengthening
the REporting of Genetic Association Studies (STREGA):
an extension of the STROBE statement. PLoS Med
2009;6:e22.
63. Wu Z, Weng DSD, Thenappan A, et al. Evaluation of a
region-of-interest approach for detecting progressive
glaucomatous macular damage on optical coherence
tomography. Transl Vis Sci Technol 2018;7:14.
64. de Vries-Knoppert WA, Baaijen JC, Petzold A. Patterns of
retrograde axonal degeneration in the visual system.
Brain 2019;142:2775–2786.
65. Jindahra P, Petrie A, Plant GT. The time course of
retrograde trans-synaptic degeneration following occipital
lobe damage in humans. Brain 2012;135:534–541.
66. Panneman E, Coric D, Tran L, et al. Progression of
anterograde trans-synaptic degeneration in the human
retina is modulated by axonal convergence and
divergence. Neuro-Ophthalmol 2019;43:382–390.
67. Jindahra P, Petrie A, Plant GT. Retrograde trans-synaptic
retinal ganglion cell loss identified by optical coherence
tomography. Brain 2009;132:628–634.
68. Sinnecker T, Oberwahrenbrock T, Metz I, et al. Optic
radiation damage in multiple sclerosis is associated with
visual dysfunction and retinal thinning - an ultrahigh-
field MR pilot study. Eur Radiol 2014;25:122–131.
69. Gelfand JM, Nolan R, Schwartz DM, et al. Microcystic
macular oedema in multiple sclerosis is associated with
disease severity. Brain 2012;135:1786–1793.
70. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic
macular oedema, thickness of the inner nuclear layer of
the retina, and disease characteristics in multiple sclerosis:
a retrospective study. Lancet Neurol 2012;11:963–972.
71. Gelfand JM, Cree BA, Nolan R, et al. Microcystic inner
nuclear layer abnormalities and neuromyelitis optica.
JAMA Neurol 2013;1–5.
72. Knier B, Schmidt P, Aly L, et al. Retinal inner nuclear
layer volume reflects response to immunotherapy in
multiple sclerosis. Brain 2016;139:2855–2863.
73. Balk LJ, Coric D, Knier B, et al. Retinal inner nuclear
layer volume reflects inflammatory disease activity in
multiple sclerosis; a longitudinal OCT study. Mult Scler J
Exp Transl Clin 2019;5(3):205521731987158.
74. Burggraaff MC, Trieu J, de Vries-Knoppert WAEJ, et al.
The clinical spectrum of microcystic macular edema.
Invest Ophthalmol Vis Sci 2014;55:952–961.
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 13
A. Petzold et al. OSCAR-AI
75. Brandt AU, Oberwahrenbrock T, Kadas EM, et al.
Dynamic formation of macular microcysts independent
of vitreous traction changes. Neurology 2014;83:73–77.
76. Balk LJ, Killestein J, Polman CH, et al. Microcystic
macular oedema confirmed, but not specific for multiple
sclerosis. Brain 2012;135:e226.
77. Abegg M, Dysli M, Wolf S, et al. Microcystic macular
edema: retrograde maculopathy caused by optic
neuropathy. Ophthalmology 2014;121:142–149.
78. van Buren J. Trans-synaptic retrograde degeneration in
the visual system of primates. J Neurol Neurosurg
Neuropsych 1963;26:402–409.
79. Kleerekooper I, Petzold A, Trip SA. Anterior visual
system imaging to investigate energy failure in multiple
sclerosis. Brain 2020;143(7):1999–2008.
80. Keane PA, Balaskas K, Sim DA, et al. Automated analysis
of vitreous inflammation using spectral-domain optical
coherence tomography. Transl Vis Sci Technol. 2015;4
(5):4–10.
81. Montesano G, Way C, Ometto G, et al. Optimizing OCT
acquisition parameters for assessments of vitreous haze
for application in uveitis. Sci Rep 2018;8:1648.
82. Coric D, Ometto G, Montesano G, et al. Objective
quantification of vitreous haze on optical coherence
tomography scans: no evidence for relationship between
uveitis and inflammation in multiple sclerosis. Eur J
Neurol 2019.
83. Kaufhold F, Kadas EM, Schmidt C, et al. Optic nerve
head quantification in idiopathic intracranial
hypertension by spectral domain OCT. PLoS One 2012;7:
e36965.
84. Albrecht P, Blasberg C, Ringelstein M, et al. Optical
coherence tomography for the diagnosis and monitoring
of idiopathic intracranial hypertension. J Neurol
2017;264:1370–1380.
85. Albrecht P, Blasberg C, Lukas S, et al. Retinal pathology
in idiopathic moyamoya angiopathy detected by optical
coherence tomography. Neurology 2015;85:521–527.
86. Malmqvist L, Bursztyn L, Costello F, et al. The optic disc
drusen studies consortium recommendations for
diagnosis of optic disc drusen using optical coherence
tomography. J Neuroophthalmol 2018;38:299–307.
87. Yadav SK, Motamedi S, Oberwahrenbrock T, et al. CuBe:
parametric modeling of 3D foveal shape using cubic
Bezier. Biomedical Optics Express 2017;8:4181–4199.
88. Motamedi S, Oertel FC, Yadav SK, et al. Altered fovea in
AQP4-IgG–seropositive neuromyelitis optica spectrum
disorders. Neurol Neuroimmunol Neuroinflamm 2020;7:
e805.
89. Bennett MR, Farnell L, Gibson WG. Quantitative
relations between transient BOLD responses, cortical
energetics, and impulse firing in different cortical regions.
J Neurophysiol 2019;122:1226–1237.
90. Feucht N, Maier M, Lepennetier G, et al. Optical
coherence tomography angiography indicates associations
of the retinal vascular network and disease activity in
multiple sclerosis. Multiple Sclerosis J 2018;25:224–234.
91. Murphy OC, Kwakyi O, Iftikhar M, et al. Alterations in
the retinal vasculature occur in multiple sclerosis and
exhibit novel correlations with disability and visual
function measures. Multiple Sclerosis J 2019;26:815–828.
92. Iftikhar M, Zafar S, Gonzalez N, et al. Image artifacts in
optical coherence tomography angiography among
patients with multiple sclerosis. Curr Eye Res
2019;44:558–563.
93. Kleerekooper I, Houston S, Dubis AM, et al. Optical
coherence tomography angiography (OCTA) in multiple
sclerosis and neuromyelitis optica spectrum disorder.
Front Neurol 2020;11.
94. Petzold A, Wattjes MP, Costello F, et al. The
investigation of acute optic neuritis: a review and
proposed protocol. Nat Rev Neurol 2014;10(8):
447–458.
95. Coric D, Balk LJ, Uitdehaag BMJ, Petzold A. Diagnostic
accuracy of optical coherence tomography Inter-Eye
Percentage Difference (IEPD) for optic neuritis in
multiple sclerosis. Eur J Neurol 2017;24:1479–1484.
96. Nolan-Kenney RC, Liu M, Akhand O, et al. Optimal
intereye difference thresholds by optical coherence
tomography in multiple sclerosis: an international study.
Ann Neurol 2019;85:618–629.
97. Xu SC, Kardon RH, Leavitt JA, et al. Optical coherence
tomography is highly sensitive in detecting prior optic
neuritis. Neurology 2019;92:e527–e535.
98. Behbehani R, Ali A, Al-Omairah H, Rousseff RT.
Optimization of spectral domain optical coherence
tomography and visual evoked potentials to identify
unilateral optic neuritis. Mult Scler Relat Disord
2020;41:101988.
99. Davion J-B, Lopes R, Drumez E, et al. Asymptomatic
optic nerve lesions. Neurology 2020;94(23):e2468–e2478.
100. Outteryck O, Lopes R, Drumez E, et al. Optical
coherence tomography for detection of asymptomatic
optic nerve lesions in clinically isolated syndrome.
Neurology 2020;95:e733–e744.
101. Villoslada P, Sanchez-Dalmau B, Galetta S. Optical
coherence tomography: A useful tool for identifying
subclinical optic neuropathy in diagnosing multiple
sclerosis. Neurology 2020;95:239–240.
102. Burns SA, Elsner AE, Sapoznik KA, et al. Adaptive optics
imaging of the human retina. Prog Retin Eye Res
2019;68:1–30.
103. Romano F, Arrigo A, Leone PP, et al. Altered ellipsoid
zone reflectivity and deep capillary plexus rarefaction
correlate with progression in Best disease. Br J
Ophthalmol 2020;104:461–465.
14 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
OSCAR-AI A. Petzold et al.
Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Text S1. List of committee members: IMSVISUAL and
ERN-EYE.
ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association 15
A. Petzold et al. OSCAR-AI
